Maxim Group set a $6.00 price objective on Sophiris Bio (NASDAQ:SPHS) in a research note published on Monday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a buy rating and set a $6.00 price objective on shares of Sophiris Bio in a research note on Friday, November 10th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $6.25.

Sophiris Bio (NASDAQ SPHS) opened at $2.05 on Monday. The company has a quick ratio of 13.37, a current ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a 52 week low of $1.80 and a 52 week high of $3.24.

An institutional investor recently bought a new position in Sophiris Bio stock. Mesirow Financial Investment Management Inc. acquired a new position in Sophiris Bio Inc (NASDAQ:SPHS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned about 0.18% of Sophiris Bio as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.56% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Sophiris Bio (SPHS) Given a $6.00 Price Target at Maxim Group” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/sophiris-bio-sphs-given-a-6-00-price-target-at-maxim-group/1759092.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.